Oncology Clinical Pathways Spotlight
This week in health care trends, our spotlight on oncology clinical pathways and utilization management includes updates about a new pathways collaboration, breast cancer therapy adherence, and the future of clinical pathways.
The four articles below are from our dedicated Oncology Clinical Pathways e-magazine. We’re constantly adding valuable content to this updateable magazine, so make sure to check our e-magazine frequently for new intelligence. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)
In a recent newsletter, Aurora Cancer Care announced that they would be “going live” with VIA Oncology in October (see page 3) to “provide decision support to [their] oncology physicians.”
In discussions about clinical pathways, adherence is an oft-mentioned issue. A recent study of breast cancer patients prescribed aromatase inhibitors (AIs) published in the Journal of the National Cancer Institute found that “women who took generic AIs were 50 percent more likely to adhere to their drug therapy than those who took brand-name AIs.”
As clinical pathways program continue to expand, the American Journal of Managed Care convened a panel of thought leaders to discuss how pathways are changing cancer care. Leaders from organizations like ASCO, Wellpoint, and others talked about the fine line between pathways and guidelines and the different types of pathways.
As a part of its growing oncology support service offerings, Cardinal Health Specialty announced that “through an agreement with KEW Group (Cambridge, MA), oncologists participating in the Cardinal health Specialty Solutions network have access to KEW’s CancerPlex, a molecular diagnostic system that analyzes the genetics of individual patients’ tumors.”